(Q38732069)

5 September 2017

title

Resveratrol inhibits Hexokinases II mediated glycolysis in non-small cell lung cancer via targeting Akt signaling pathway (English)

1 reference

5 September 2017

1 reference

Wei Li

1

1 reference

5 September 2017

Xiaoqian Ma

2

1 reference

5 September 2017

Na Li

3

1 reference

5 September 2017

Huasheng Liu

4

1 reference

5 September 2017

Qiong Dong

5

1 reference

5 September 2017

Juan Zhang

6

1 reference

5 September 2017

Cejun Yang

7

1 reference

5 September 2017

Yin Liu

8

1 reference

5 September 2017

Qi Liang

9

1 reference

5 September 2017

Shengwang Zhang

10

1 reference

5 September 2017

Chang Xu

11

1 reference

5 September 2017

Wei Song

12

1 reference

5 September 2017

Shiming Tan

13

1 reference

5 September 2017

Pengfei Rong

14

1 reference

5 September 2017

Wei Wang

15

1 reference

5 September 2017

language of work or name

English

0 references

publication date

6 November 2016

1 reference

Experimental Cell Research

5 September 2017

published in

1 reference

5 September 2017

volume

349

1 reference

5 September 2017

issue

2

1 reference

5 September 2017

page(s)

320-327

1 reference

Non-small-cell lung cancers: a heterogeneous set of diseases

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Cancer treatment and survivorship statistics, 2014

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Resveratrol and cancer: Challenges for clinical translation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Lifespan and healthspan extension by resveratrol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

The pharmacology of resveratrol in animals and humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

The molecular targets of resveratrol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Resveratrol as a novel treatment for diseases with mTOR pathway hyperactivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Hallmarks of Cancer: The Next Generation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Otto Warburg's contributions to current concepts of cancer metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Oncogenic viruses and tumor glucose metabolism: like kids in a candy store

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Metabolic reprogramming of the tumour microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Tumor glycolysis as a target for cancer therapy: progress and prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

How do glycolytic enzymes favour cancer cell proliferation by nonmetabolic functions?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Targeting cellular metabolism to improve cancer therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Targeting VDAC-bound hexokinase II: a promising approach for concomitant anti-cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Epidermal growth factor receptor mutations in lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Gefitinib--a novel targeted approach to treating cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Refining the treatment of NSCLC according to histological and molecular subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Resveratrol inhibits proliferation and induces apoptosis through the hedgehog signaling pathway in pancreatic cancer cell.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

AKT/PKB signaling: navigating downstream

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Targeting the phosphoinositide 3-kinase pathway in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Tumor suppressors and cell metabolism: a recipe for cancer growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Hypoxia, HIF1 and glucose metabolism in the solid tumour

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Epigallocatechin gallate inhibits human tongue carcinoma cells via HK2‑mediated glycolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Bergapten induces metabolic reprogramming in breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2016.11.002

10.1016/J.YEXCR.2016.11.002

7 January 2021

Identifiers

DOI

1 reference

5 September 2017

1 reference